anti-Noggin, pAb

CHF 322.00
In stock
YIF-LF-PA0092100 µlCHF 322.00
More Information
Product Details
Synonyms NOG; Noggin
Product Type Polyclonal Antibody
Properties
Immunogen/Antigen Synthetic peptide.
Application

Western Blot (1:1,000)

Crossreactivity Human
Mouse
Concentration 1 mg/ml
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Noggin is a 32 kDa glycoprotein that binds to bone morphogenetic protein (BMP) and antagonizes the action of them. Bone morphogenetic proteins were originally identified by an ability of demineralized bone extract to induce endochondral osteogenesis in vivo. BMPs also regulate cell proliferation, differentiation, lineage determination, motility, and death. BMP antagonists include noggin, chordin, follistatin, ventroptin, twisted gastrulation, Dan, and gremlin etc. They play a crucial role in bone development, by regulating the BMP functions. Noggin plays a key role in neurulation by inhibiting BMP4, along with other morphogens such as chordin and follistatin and in the formation of the neural plate. Noggin inhibits BMP signaling by blocking the molecular interfaces of the binding epitopes for both type I and type II receptors. It antagonizes the action of BMPs, and induces neural tissue and dorsalizes ventral mesoderm. Essential for cartilage morphogenesis and joint formation. Inhibitor of bone morphogenetic proteins (BMP) signaling which is required for growth and patterning of the neural tube and somite.

Product References

1) Chang KH et al., (2007) Circulation. 116:1258-1266. (General)
2) Yanagita M, (2005) Cytokine Growth Factor Rev. 16(3):309-317. (General)
3) Canalis E et al., (2003) Endocr Rev. 2003 24(2):218-235. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.